Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.
Rebecca Bigler, PhD
Advertisement
Articles by Rebecca Bigler, PhD
Advertisement
Latest Updated Articles
CAR T-Cell Therapy: Genetically Programming the Immune System to Attack Malignant CellsPublished: February 25th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Poherdy, First Biosimilar to Perjeta, For HER2 Breast Cancer Indications
2
A Common Virus May Hold New Clues to Lupus
3
Study Finds Similar Outcomes Between hMPV and RSV Hospitalizations
4
Managing Safety and Supportive Care With Pluvicto: Insights From the PSMAddition Trial
5
